Zomedica Corp.

Equities

ZOM

CA98980M1095

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 04:10:00 2024-04-29 pm EDT			5-day change	1st Jan Change
0.1395 ^USD	+4.89%		+7.23%	-30.32%

Apr. 01	Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 01	Zomedica Seeks Acquisitions	CI

Zomedica Corp. Reiterates Revenue Guidance for Full Year 2024

April 01, 2024 at 04:05 pm EDT

Zomedica Corp. reiterated revenue guidance for full year 2024. For the period, the company expects revenue in the range of $31 to $35 million, an increase of approximately 40% at the high end of the range, over full year 2023 revenue of $25.2 million.

Latest news about Zomedica Corp.

Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Zomedica Seeks Acquisitions	Apr. 01	CI
Transcript : Zomedica Corp., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Earnings Flash (ZOM) ZOMEDICA Posts Q4 Revenue $7.3M	Apr. 01	MT
Zomedica Corp. Reiterates Revenue Guidance for Full Year 2024	Apr. 01	CI
Zomedica Corp. Announces Publication of Research Con Including TRUFORMA(R) Platform Is More Accurate Diagnostic Test for Feline Hyperthyroidism Than Chemiluminescent Immunoassay Platform	Mar. 14	CI
Transcript : Zomedica Corp. - Shareholder/Analyst Call	Feb. 28
Transcript : Zomedica Corp. - Analyst/Investor Day	Feb. 13
Zomedica Pharmaceuticals Reports Preliminary Q4 Revenue	Jan. 17	MT
Transcript : Zomedica Corp., 2023 Sales/ Trading Statement Call, Jan 17, 2024	Jan. 17
Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024	Jan. 17	CI
Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease	Dec. 18	CI
Zomedica Announces Presentation of Clinical Data in Support of New Indications for Pulsevet Shock Wave Therapy	Dec. 06	CI
Earnings Flash (ZOM) ZOMEDICA Posts Q3 Revenue $6.3M	Nov. 13	MT
Transcript : Zomedica Corp., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Zomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Zomedica Corp. acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc. for $11.3 million.	23-10-04	CI
Zomedica Corp. Launches its Newest Assay - Endogenous ACTH	23-09-14	CI
Zomedica Pharmaceuticals Issued Warning From NYSE American For Failing to Meet Listing Requirement	23-09-13	MT
Zomedica Completes Acquisition of Structured Monitoring Products	23-09-05	MT
Earnings Flash (ZOM) ZOMEDICA Posts Q2 Revenue $6M	23-08-10	MT
Zomedica Seeks M&A Opportunities	23-08-10	CI
Transcript : Zomedica Corp., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Zomedica Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : Zomedica Corp. - Shareholder/Analyst Call	23-06-13

Chart Zomedica Corp.

Duration

Period

More charts

Company Profile

Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.

Sector

Healthcare Facilities & Services

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar